The Financial Burden of Prescribed Medications in COPD
Jeenat Mehareen, Mohsen Sadatsafavi, Phalgun Joshi, Chris Carlsten, Joseph Emil Amegadzie · 2026
Read The Financial Burden of Prescribed Medications in COPD by Jeenat Mehareen, Mohsen Sadatsafavi, Phalgun Joshi, Chris Carlsten, Joseph Emil Amegadzie (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13543011.txt.
Description
Jeenat Mehareen and co-authors published a 2026 study measuring how much extra people with chronic obstructive pulmonary disease spend on medicines, and who pays. Using British Columbia health databases spanning 2001 to 2020, the team matched more than 207,000 patients with physician-diagnosed COPD to over 400,000 people without the disease. Excess cost was the adjusted difference in all medication spending, split between the public PharmaCare programme and private sources such as out-of-pocket payments.
Patients with COPD spent an extra 1,336 Canadian dollars per patient-year on medications. About forty percent of that excess, 528 dollars, was privately financed, and private spending grew much faster than public spending across the two decades, at roughly 8 percent a year. Patients also personally bore half of their inhaler costs. The authors warn that the private share of drug costs quietly shifts the burden of chronic lung disease onto patients.
Catalog record
| CREATOR | Jeenat Mehareen, Mohsen Sadatsafavi, Phalgun Joshi, Chris Carlsten, Joseph Emil Amegadzie |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29272 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |